Foxy-5 TFA
Based on 7 publication(s) in Google Scholar
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.17%
- Formule: C28H43F3N6O14S2
- Masse moléculaire:808.80
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Foxy-5 TFA
More- Int J Oral Sci. 2024 Feb 19;16(1):15. [Abstract]
- J Neuroinflammation. 2024 Mar 26;21(1):75. [Abstract]
- Phytomedicine. 2025 Feb 10:139:156491. [Abstract]
- Int Immunopharmacol. 2026 Mar 1:172:116168. [Abstract]
- iScience. 2024 Dec 1;27(12):111517. [Abstract]
- Pathol Res Pract. 2024 May 26:259:155369. [Abstract]
- Patent. US20230130144A1.
Activité biologique
|
Wnt5A |
Foxy-5 TFA (100 μM, 24 h) inhibits the invasion of tumor cells in DU145 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145, PC3
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reduced DU145 cell invasion by 40%.
Foxy-5 TFA (2 mg/kg, intraperitoneal injection, once a day, for 3-9 weeks) significantly reduces the early metastasis and spread of WNT5A low DU145 prostate cancer cells in a mouse model of prostate cancer xenotransplantation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A Xenograft Mouse Model of Human Colonic Cancer[2]
-
Dosage:2 mg/kg
-
Administration:i.p. 9 times a day for 7-23 days
-
Result:Reduced the expression of ALDH, DCLK1 and COX-2.
Increased the expression of 15-PGDH.
Reduced the expression of the downstream β-catenin target ASCL2.
-
Animal Model:A Xenograft Mouse Model of Prostate Cancer [3]
-
Dosage:2 mg/kg
-
Administration:i.p. once a day, for 3-9 weeks
-
Result:Reduced metastatic spread and the number of tumor cells in lymph nodes.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Solid
-
Masse moléculaire 808.80
-
Formule C28H43F3N6O14S2
-
Color White to off-white
-
Sequence
{For}-Met-Asp-Gly-Cys-Glu-Leu
-
Sequence Shortening
{For}-MDGCEL
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Int J Oral Sci
2024 Feb 19;16(1):15. PMID: 38369512 -
J Neuroinflammation
Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration. [Abstract]2024 Mar 26;21(1):75. PMID: 38532410 -
Phytomedicine
Quercetin improves airway remodeling in COPD rats by suppressing phenotypic switch of ASMCs via inhibiting the Wnt5a/β-catenin pathway. [Abstract]2025 Feb 10:139:156491. PMID: 39955824 -
Int Immunopharmacol
Piezo1 activates Wnt5a/FZD4 signaling to promote osteogenesis and mitigates age-associated bone loss. [Abstract]2026 Mar 1:172:116168. PMID: 41529412 -
iScience
The mesenteric adipokine SFRP5 alleviated intestinal epithelial apoptosis improving barrier dysfunction in Crohn's disease. [Abstract]2024 Dec 1;27(12):111517. PMID: 39759008 -
Pathol Res Pract
PC4 promotes bladder cancer progression and stemness by directly interacting with Sp1 to transcriptionally activate the Wnt5a/β-catenin pathway. [Abstract]2024 May 26:259:155369. PMID: 38820928 -
Solvant et solubilité
DMSO : ≥ 100 mg/mL (123.64 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 3.33 mg/mL (4.12 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Saline
Solubility: 5 mg/mL (6.18 mM); Clear solution; Need ultrasonic
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63. [Content Brief]
[2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728. [Content Brief]
[3]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.2364 mL | 6.1820 mL | 12.3640 mL | 30.9100 mL |
| DMSO | 5 mM | 0.2473 mL | 1.2364 mL | 2.4728 mL | 6.1820 mL |
| 10 mM | 0.1236 mL | 0.6182 mL | 1.2364 mL | 3.0910 mL | |
| 15 mM | 0.0824 mL | 0.4121 mL | 0.8243 mL | 2.0607 mL | |
| 20 mM | 0.0618 mL | 0.3091 mL | 0.6182 mL | 1.5455 mL | |
| 25 mM | 0.0495 mL | 0.2473 mL | 0.4946 mL | 1.2364 mL | |
| 30 mM | 0.0412 mL | 0.2061 mL | 0.4121 mL | 1.0303 mL | |
| 40 mM | 0.0309 mL | 0.1545 mL | 0.3091 mL | 0.7727 mL | |
| 50 mM | 0.0247 mL | 0.1236 mL | 0.2473 mL | 0.6182 mL | |
| 60 mM | 0.0206 mL | 0.1030 mL | 0.2061 mL | 0.5152 mL | |
| 80 mM | 0.0155 mL | 0.0773 mL | 0.1545 mL | 0.3864 mL | |
| 100 mM | 0.0124 mL | 0.0618 mL | 0.1236 mL | 0.3091 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Foxy-5 TFA Related Classifications
HY-P1416A Related Classifications
Powered by Bioz